419 results about "Resistant organism" patented technology

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof:

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention belongs to the technical field of medicines and particularly relates to a new function of micromolecular metabolin, namely glutamine. The micromolecule can improve the sensitivity of bacteria including drug-resistant bacteria to antibiotics so as to solve the problem of drug resistance of bacteria. The micromolecule provided by the invention has better effect and higher safety and operability compared with antibiotic which is applied to the medicament for resisting drug resistance of bacteria at present.

The invention belongs to the field of biological medicines, and discloses a novel use of a small molecule compound alanine. The research shows that the alanine is capable of enhancing the effect of the antibiotic to kill pathogenic bacteria including drug-resistance bacteria. The small molecule metabolite alanine provided by the invention can be used as a medicine for improving the sterilizing function of the antibiotic.

The invention belongs to the technical field of disinfectants, and discloses a leave-on skin care and disinfection gel containing a composite sterilization component. The leave-on skin care and disinfection gel is prepared through the following steps: immersing a humectant in deionized water 2 days ahead to dissolve the humectant; stirring and dissolving a thickener in water 1 day ahead; and taking an antibacterial agent at normal temperature, dissolving the antibacterial agent in ethanol, adding a quaternary ammonium salt disinfectant and a biguanide disinfectant, adding the above obtained completely dissolved thickener solution and the obtained dissolved humectant solution, stirring until uniformity, adjusting the pH value to 5.0-7.5 by using a neutralizer, adding deionized water to a full dose, stirring until uniformity, and solidifying. The disinfection gel enlarges the antibacterial spectrum range, is in favor of preventing generation of drug resistant bacteria, has the characteristics of no irritation, quick action and long action, overcomes disadvantages of sing composition disinfectants, and also has a skin care effect.

The invention provides an anti-IMP type carbapenemase hybridoma cell strain, a monoclonal antibody and application. The hybridoma cell strain capable of stably secreting an anti-IMP type carbapenemaseantibody and a variable region sequence of the hybridoma cell strain are obtained by screening a mouse hybridoma monoclonal antibody and cloning an Ig variable region gene by an RT-PCR method, and the antibody binding specificity is identified by an ELISA method; the obtained anti-IMP type carbapenemase antibody can be used for detecting IMP type carbapenemase, the titer reaches 1:640000 or more,and the anti-IMP type carbapenemase antibody can be prepared into an in-vitro diagnostic kit or microfluidic chip for early typing of drug-resistant strains, guiding medication and assisted clinicalinfection control and treatment, and has important significance for improving the medical and health level of China.

The invention discloses antibacterial peptides and application of the antibacterial peptides to preparation of a medicament resisting drug-resistant bacteria. The antibacterial peptides consist of 21 amino acids, wherein the amino acid sequence is shown as SEQIDNO.1. The in-vivo and in-vitro research shows that six kinds of antibacterial peptides have a strong inhibiting and killing action for the mostly clinically-separated drug-resistant bacteria and can remarkably reduce the mortality of a septicemia model caused by the drug-resistant bacteria; and a hemolytic test and an acute local stimulus test results show that six kinds of derivates have no hemolytic test or acute toxic stimulus reaction when the concentration is 2.5mg/mL.

The present invention belongs to the field of screening antituberculotic target, vaccine antigen and detecting target in molecular biological technology, and is especially process of screening protein resisting rifampicin as antituberculotic. The process includes the first culturing drug resistant strain, the subsequent separating protein of drug resistant strain from protein of sensitive strain, comparing protein of drug resistant strain and protein of sensitive strain to determine the drug resistant protein, and final separating and identifying drug resistant protein. The process of the present invention can separate and identify drug resistant protein of Mycobacterium tuberculosis to provide new way for further understanding the drug resisting mechanism of Mycobacterium tuberculosis, fast clinical detection of drug resistant strain, and developing vaccine and medicine.

The invention discloses application of elsholtzia volatile oil in anti-bacteria and antibiotic resistant bacteria. The elsholtzia volatile oil is extracted by steam distillation. The elsholtzia volatile oil has certain functions of killing and/or inhibiting growth on bacteria of staphylococcus, escherichia coli, candida, pseudomonas, enterobacter, streptococcus and the like and fungi. The elsholtzia volatile oil has certain functions of killing and/or inhibiting growth on bacteria of drug-resistant staphylococcus, drug-resistant escherichia coli, drug-resistant enterobacter, drug-resistant klebsiella, drug-resistant pseudomonas, drug-resistant acinetobacter, drug-resistant streptococcus, and drug-resistant enterococcus and the like. The elsholtzia volatile oil can be used in industries offood, medicine, health care products, cosmetics and the like and can be used for preparing various forms of products with antibacterial and antibiotic resistant bacteria functions, and belongs to thenew application field of the elsholtzia volatile oil.

The invention provides a compound with antibacterial synergism as well as a preparation method and application thereof. The compound has stronger antibacterial synergism, can remarkably improve antibacterial effect, especially for drug-resistant strains while being combined with antibacterial drugs for use. Especially in case of being combined with macrolide antibiotics and the like for use, the compound achieves antibacterial synergism, can assist antibiotics to restrain or kill sensitive bacteria and drug-resistant bacteria, for example staphylococcus aureus which is sensitive and drug-resistant to erythromycin. By adopting the compound and a pharmaceutically acceptable carrier, a pharmaceutical composition and a medicinal preparation can be prepared and antibacterial drug synergist can also be prepared.

The invention relates to gopalamicin derivatives and application of the same in inhibition of infection by drug-resistant bacteria and drug-resistant mycobacterium tuberculosis. The derivatives are originated from fermentation products of marine actinomycete Streptomyces sp. 7-145. Results of experimental study show that discovered compounds with novel structures and known structures all have strong antibacterial activity on tested drug-resistant bacteria and drug-resistant mycobacterium tuberculosis and are expected to become clinically-useful novel drugs used for inhibition of infection by drug-resistant bacteria and drug-resistant mycobacterium tuberculosis.

The invention relates to ainsliaea fragrans champ caffeoylquinic acid extracts and preparation and application thereof. The ainsliaea fragrans champ caffeoylquinic acid extracts are prepared by the following steps of: performing refluxing extraction of the ainsliaea fragrans champ by using ethanol, filtering, concentrating and removing ethanol, adjusting the pH value to 1 to 3 by adding hydrochloric acid, applying macroporous adsorbent resin, water-washing, adding ethanol for gradient elution, and collecting eluent, of which the ethanol concentration is 50 to 70 percent; performing condensation and ethanol removal, adjusting the pH value to 1 to 3 by adding hydrochloric acid, using macroporous adsorbent resin, adding water and ethanol for gradient elution respectively, and collecting the eluent, of which the ethanol concentration is 40 to 70 percent; mixing the eluent, and vacuum drying the eluent to obtain the extracts. The UV content of the ainsliaea fragrans champ caffeoylquinic acid extracts is over 70 percent, the HPLC content is over 50 percent, and the content of 3-caffeoylquinic acid and the content of 3,5-dicaffeoylquinic acid are both over 10 percent. The ainsliaea fragrans champ caffeoylquinic acid extracts have the effects of resisting inflammations, bacteria, medicament-resistant strains, well improves pathologically changed tissues of rat suffering from cervicitis, obviously reduces the uterus index and the number of leukocytes and can be independently prepared into the medicaments for treating cervicitis or combined with other medicaments to prepare the medicaments for treating cervicitis.

The invention discloses a preparation method for a dichloro substituted II-type halogenated polyketone compound zunyimycin A, wherein the compound is derived from a secondary metabolite of a streptomyces sp.FJS31-2 strain (with the strain preservation number of CGMCC4.7321), and finally, a structure is identified and determined after strain activation, expansion culture and isolation. The compoundcan be used in treatment of diseases infected by gram-positive bacteria such as staphylococcus aureus (MRSA) and drug-resistant bacteria thereof, staphylococcus epidermidis, bacillus subtilis and thelike, is used in treatment of diseases infected by gram-negative bacteria such as super-spectrum beta-lactamase escherichia coli (ESBL), proteusbacillus vulgaris, bacterium burgeri and the like, andis used for treatment of diseases infected by fungi, such as candida albicans.

The invention discloses application of dihydroquercetin and glucoside compounds to preparing a medicine for resisting drug-fast bacteria. With the invention, the dihydroquercetin and glucoside compounds can be extracted from decogenus plants, such as hypericum japonicum Thunb, and the activity of the dihydroquercetin and glucoside compounds for resisting the drug-fast bacteria can be proved; proved by a pharmacological experiment, the dihydroquercetin and glucoside compounds not only have remarkable direct inhibition function on common-clinically meticillin-resistant staphylococcus aureus (MRSA), but also can enhance the action of the traditional antibiotic for resisting the drug-fast bacteria. The dihydroquercetin and glucoside compounds can be further used as active components and used for preparing a medicine for treating the drug-fast bacteria infection; and preparation forms includes oral preparations, injections and/or external preparations which are prepared by combining with acceptable carriers.

The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.

The invention provides a medicine composition taking medicines which benefit qi and activate blood circulation and clear away heat and toxic materials for compatibility. The medicine composition has exact treatment effects on various inflammations caused by standard bacteria strains and medicine resistant strains (such as KPC positive or superbacteria NDM-1 positive) such as respiratory tract infection, pelvic cavity infection, urinary infection and acute peritonitis. The medicine composition is a combined preparation of one or more of radix astragali, ginseng, American ginseng, dangshen, heterophylly falsestarwort root, largehead atractylodes rhizome, liquorice and Chinese yam, one or more of salvia miltiorrhiza, red peony root, leeches, Sichuan lovage rhizome, safflower, peach kernels, pseudo-ginseng, rosewood, rhizoma corydalis, ground beetle, motherwort herb, Chinese angelica and giant knotweed rhizome and one or more of honeysuckle, weeping forsythia capsule, isatis root, dyers woad leaf, dandelion, baical skullcap root, heartleaf houttuynia herb, dahurian patrinia herb, common andrographis herb, Tokyo violet herb, herba corydalis bungeanae, gueldenstaedtia multiflora bunge, globeflower and wild chrysanthemum in clinically reasonable doses.

The invention discloses a preparation method and application of a zinc organic framework composite material for photoresponsively releasing vancomycin. The composite material is formed by encapsulating vancomycin in a zinc organic framework and further modifying the surface of the zinc organic framework with polydopamine, and the material is called Van @ ZIF-8 @ PDA for short, wherein Van is vancomycin, ZIF-8 is the zinc organic framework, and PDA is polydopamine. The preparation method comprises the following steps of: firstly, dissolving vancomycin and zinc nitrate hexahydrate in an aqueoussolution, and mixing and stirring; then dropwise adding a 2-methylimidazole solution, stirring again, and then performing centrifugal washing and vacuum drying to obtain the zinc organic framework (Van @ ZIF-8 @ PDA) encapsulating vancomycin; and then adding dopamine into a Tris-HCl solution of Van @ ZIF-8, mixing and stirring, and performing centrifugal washing and vacuum drying to obtain the Van@ ZIF-8 @ PDA composite material. The invention belongs to the field of antibacterial drugs, and the composite material as a novel antibacterial drug has a remarkable inhibiting effect on vancomycin-mediated drug-resistant staphylococcus aureus Mu50 and a biological membrane thereof, can remarkably reduce the working concentration of antibiotics, and has a huge potential in treatment of drug-resistant bacteria.